Minopafant

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C46H73N4O9.Cl
Molecular Weight	861.546
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Cl-].CCCCCCCCCCCCCCCCCCNC(=O)OC1CCN(CC1)C(=O)OC[C@H](COC(=O)N(CC2=CC=CC=[N+]2CC)C(=O)C3=CC=CC=C3OC)OC

InChI

InChIKey=IXRMFSBOHHRXSS-YPMTVOEDSA-N

InChI=1S/C46H72N4O9.ClH/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-31-47-44(52)59-39-29-33-49(34-30-39)45(53)57-36-40(55-3)37-58-46(54)50(35-38-26-23-25-32-48(38)6-2)43(51)41-27-21-22-28-42(41)56-4;/h21-23,25-28,32,39-40H,5-20,24,29-31,33-37H2,1-4H3;1H/t40-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C46H73N4O9
Molecular Weight	826.0932
Charge	1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800002131 | https://www.ncbi.nlm.nih.gov/pubmed/1663352

Minopafant (E5880) is a novel platelet activating factor receptor antagonist. Minopafant had been in phase II clinical trials by Eisai in Japan for the treatment of disseminated intravascular coagulation. However, this research has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Platelet activating factor receptor 20 Target ID: CHEMBL250 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1663352	Antagonist 2778		0.27 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Disseminated intravascular coagulation 8 Sources: http://adisinsight.springer.com/drugs/800002131 https://www.ncbi.nlm.nih.gov/pubmed/8191415	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures.	1997 Apr 18	9134961

Patents

Sample Use Guides

In Vivo Use Guide

Intravenous Minopafant administration (300 ug or 1200 ug twice daily) was begun within 4 days and continued for 14 days.

Route of Administration: Intravenous

In Vitro Use Guide

Minopafant (E5880) was tested for its neuroprotective activity in primary neuronal cultures isolated from embryonic rat cerebral cortex. Protective effect was observed in cultures treated with E5880 (P < 0.01 at 10 nM E5880)

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:49:05 GMT 2023` Edited by `admin` on `Fri Dec 15 18:49:05 GMT 2023`
Record UNII	I7J5MAD9ZU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Minopafant

Official Name

English

E5880

Code

English

minopafant [INN]

Common Name

English

Minopafant chloride

Common Name

English

E-5880

Code

English

Pyridinium, 1-ethyl-2-[[(2-methoxybenzoyl)[[(2R)-2-methoxy-3-[[[4-[[(octadecylamino)carbonyl]oxy]-1-piperidinyl]carbonyl]oxy]propoxy]carbonyl]amino]methyl]-, chloride

Systematic Name

English

MENOPAFANT

Common Name

English

Pyridinium, 1-ethyl-2-[[(2-methoxybenzoyl)[[(2R)-2-methoxy-3-[[[4-[[(octadecylamino)carbonyl]oxy]-1-piperidinyl]carbonyl]oxy]propoxy]carbonyl]amino]methyl]-, chloride (1:1)

Common Name

English

MENOPAFANT [JAN]

Common Name

English

Code System Code Type Description

CAS

128420-61-1